GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL (NASDAQ: GRAL) has announced the granting of equity awards in the form of restricted stock units (RSUs) to 15 newly hired non-executive employees. The inducement grants, totaling 108,450 shares of GRAIL's common stock, were awarded under the company's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule, with 25% vesting on February 28, 2026, and subsequent annual vestings on the same date, contingent upon continued employment with GRAIL or its subsidiaries.
GRAIL (NASDAQ: GRAL) ha annunciato l'assegnazione di premi azionari sotto forma di unità azionarie vincolate (RSU) a 15 nuovi dipendenti non esecutivi. I premi di induzione, per un totale di 108.450 azioni ordinarie di GRAIL, sono stati concessi nell'ambito del Piano di Incentivazione Azionaria di Induzione dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le RSU presentano un programma di maturazione di quattro anni, con il 25% che matura il 28 febbraio 2026, e successivi diritti annuali di maturazione nella stessa data, a condizione di un'occupazione continuativa con GRAIL o le sue filiali.
GRAIL (NASDAQ: GRAL) ha anunciado la concesión de premios en forma de unidades de acciones restringidas (RSUs) a 15 nuevos empleados no ejecutivos. Las concesiones de inducción, que suman un total de 108,450 acciones ordinarias de GRAIL, se otorgaron bajo el Plan de Incentivos de Capital de Inducción de la empresa, en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las RSUs tienen un programa de adquisición de cuatro años, con un 25% que se adquiere el 28 de febrero de 2026, y adquisiciones anuales posteriores en la misma fecha, siempre que continúe el empleo con GRAIL o sus filiales.
GRAIL (NASDAQ: GRAL)은 15명의 신입 비임원 직원에게 제한 주식 단위(RSU) 형태의 주식 보상을 부여한다고 발표했습니다. 총 108,450주의 GRAIL 보통주가 포함된 유인 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 회사의 유인 주식 인센티브 계획에 따라 수여되었습니다.
RSU는 4년의 취득 일정을 가지고 있으며, 2026년 2월 28일에 25%가 취득되고, 이후 매년 같은 날짜에 취득이 이루어지며, GRAIL 또는 그 자회사에서 계속 근무해야 합니다.
GRAIL (NASDAQ: GRAL) a annoncé l'octroi de récompenses en actions sous forme d'unités d'actions restreintes (RSUs) à 15 nouveaux employés non exécutifs. Les attributions d'incitation, totalisant 108 450 actions ordinaires de GRAIL, ont été accordées dans le cadre du Plan d'Incitation en Actions de l'entreprise, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Les RSUs présentent un calendrier d'acquisition de quatre ans, avec 25 % qui sera acquis le 28 février 2026, et des acquisitions annuelles subséquentes à la même date, sous réserve d'un emploi continu avec GRAIL ou ses filiales.
GRAIL (NASDAQ: GRAL) hat die Gewährung von Aktienauszeichnungen in Form von Restricted Stock Units (RSUs) an 15 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die Anreizvergaben, die insgesamt 108.450 Aktien von GRAILs Stammaktien umfassen, wurden im Rahmen des Unternehmensplans zur Anreizaktienvergütung gemäß der Nasdaq-Listing-Regel 5635(c)(4) vergeben.
Die RSUs haben einen vierjährigen Vesting-Zeitplan, wobei 25% am 28. Februar 2026 fällig werden, gefolgt von jährlichen Vestings am selben Datum, vorausgesetzt, dass das Arbeitsverhältnis mit GRAIL oder seinen Tochtergesellschaften fortgesetzt wird.
- None.
- None.
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over an approximately four year period, with
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302385398.html
SOURCE GRAIL, Inc.
FAQ
How many GRAL shares were granted as RSUs in the February 2025 inducement awards?
What is the vesting schedule for GRAL's February 2025 inducement RSUs?
Why did GRAIL (GRAL) issue these inducement grants?
Under which plan were GRAL's February 2025 inducement RSUs granted?
